Antibody Drug Conjugates Therapeutics Market - Pipeline Analysis, Size and Growth, 2023
The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market/report-sample
The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.
ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market/toc-sample
Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.
Chronic Pain Treatment Market Analysis, Size, Growth and Demand, 2023
The global chronic pain treatment market is expected to witness considerable growth due to current unmet medical need of chronic pain, technological advancement in pain therapeutic and diagnostic test, and increasing number of chronic diseases such as cancer, arthritis, and diabetes mellitus. In addition, increasing geriatric population and increasing disposable income are supporting the growth of the global chronic pain market. The pharmaceutical companies are actively involved in the research and development of drugs for chronic pain. Camurus is developing CAM2038, long-acting subcutaneous buprenorphine injections for the treatment of opioid dependence and pain.
Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market
Chronic pain is defined as the pain that persists for more than 3 months or longer. It adversely affects patient’s quality of life that may limit a person’s movements, which can interfere with daily activities. This difficulty in carrying out work related or other activities can lead to disability and despair. Chronic pain persists and sends pain signals to the nervous system for weeks, months or even years. It also affects the peripheral and central nervous system called neuropathy that result from damage to or pathological changes of the peripheral or central nervous system. The actual cause of chronic pain is unknown. Some people feel chronic pain without having any past injury or evidence of body damage.
A large number of pharmaceutical companies are working for the research and development of drugs for chronic pain treatment. The pipeline of the chronic pain treatment drug candidate is rich. However, certain factors such as high treatment cost through branded drugs and decreased patient compliance are the key factors for impeding the growth of the global market during the forecast period.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market/report-sample
Some of the key players operating in the global chronic pain market are Pfizer, Inc., Cara Therapeutics, Inc., Endo Pharmaceuticals Inc., Teikoku Pharma USA, Inc., Allergan plc, Purdue Pharma L.P., Mallinckrodt plc, AstraZencea plc, Jazz Pharmaceuticals plc, and Nektar Therapeutics.
Nonalcoholic Steatohepatitis Therapeutics Market - Pipeline Analysis, Size and Growth, 2023
The global nonalcoholic steatohepatitis therapeutics market is expected to witness significant growth due to current unmet medical need of NASH, scarcity of the permanent treatment of the disease, increasing prevalence of obesity, and high demand for safe and effective medication. The regulatory bodies are supporting the NASH market by providing designations and funding for speeding up the drug development process. In March 2015, obeticholic acid, an investigational Phase III clinical trial drug candidate of Intercept Pharmaceuticals Inc., received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of patients with NASH.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market/report-sample
NASH is a type of liver disease, which is characterized by liver inflammation and fat accumulation, in the absence of significant alcohol consumption. It is the more severe form of nonalcoholic fatty liver disease. In NASH, fat accumulation, hepatic inflammation and hepatic triglyceride accumulation may ultimately lead to liver cirrhosis. North America is an emerging epidemic of obesity due to NASH. According to the NIH, NASH affects 2% to 5% of Americans and it is one of the major causes of cirrhosis.
A large number of pharmaceutical companies are investing huge capital for the development of NASH therapeutics. However, certain factors such as unknown etiology, complex pathophysiology, and high treatment cost of NASH are expected to hamper the growth of the global market during the forecast period.
Explore Report at: https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market
Some of the key players operating in the global NASH therapeutics market are Genfit SA, Gilead Sciences, Inc., Novo Nordisk A/S, Intercept Pharmaceuticals, Inc., Enzo Biochem, Inc., Raptor Pharmaceutical Corp., Conatus Pharmaceuticals Inc., Zydus Cadila Healthcare Limited., Novartis AG, and Shire plc.
Advanced Visualization Market - Global Industry Analysis, Size and Growth, 2023
According to the study, the global advanced visualization market is likely to grow from $1.8 billion in 2016 to $3.8 billion by 2023. Technological advancements, increasing demand for efficient and early diagnosis of diseases, and increasing prevalence of chronic diseases have been driving the growth of the global advanced visualization market. The market is further expected to gain revenue due to increasing geriatric population and incorporation of advanced visualization solutions in mobile devices. Integration of picture archiving and communication system (PACS) and advanced visualization solutions along with the rising demand from developing nations would create ample opportunities for the global advanced visualization vendors.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/advanced-visualization-market/report-sample
As per the findings of research, hardware and software held larger share in the global market in 2016, primarily due to increasing installation of advanced visualization hardware and software in healthcare settings. The advanced visualization service market is expected to witness higher growth during the forecast period. The higher growth for services is attributed to the increasing demand for the implementation of advanced visualization solutions and training and education services. Among different type of advanced visualization solutions, enterprise-wide thin client-based solutions held larger share in the global market in 2016, and it is also expected to witness higher growth during the forecast period. Improved data storage capacity, multi-user interface, centralized post-processing solutions, streamlined analysis, and enhanced data transfer capabilities of these solutions is significantly driving the growth of the global enterprise-wide thin client-based solutions market.
There have been many technological innovations and advancements taking place in the global advanced visualization market. The integration of PACS and advanced visualization solutions significantly drives the global market. Moreover, the technological advancements in medical imaging significantly revolutionized existing clinical practices. The continuous research and development for the development of technologically advanced diagnostic imaging systems is supporting the growth of the global advanced visualization market. Magnetic resonance imaging advancements have led to the improved image quality, improved throughput and faster exam time. The technological advancements have led to the development and installation of hybrid magnetic resonance imaging advanced visualization, which overcomes the limitations of conventional imaging modalities. Similarly, the advances in the 3D and 4D ultrasound technology has also offered capabilities ranging from better visualization of congenital birth defects to dynamic and multi-planar view of the fetal heart. 4D ultrasound technology allows live motion viewing of baby’s organs and heartbeat. This increases the compliance for advanced visualization solutions globally.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=advanced-visualization-market
Key companies in the advanced visualization market are collaborating to offer better advanced visualization solutions. In November 2016, TeraRecon, released an advanced integration between iNtuition with Agfa HealthCare’s Enterprise Imaging 8.1. The combined solution provides single user interface for accessing 2D and advanced 3D applications, bi-directional communication between Agfa and TeraRecon viewers, and multi-series data loading for 3D analysis.
Some of the other key players in the market include General Electric Company, Canon, Inc., Siemens AG, Koninklijke Philips N.V, Fujifilm Holdings Corporation, Carestream Health, Agfa-Gevaert N.V., and Ziosoft.
Cartilage Repair Market - Global Industry Analysis, Size, Growth and Demand, 2023
The global cartilage repair market is witnessing considerable growth due to increasing geriatric population, increasing obesity, increasing healthcare expenditure, and growing sports related injuries. Moreover, increase in innovative product launches and growth of medical tourism leading to awareness about the cartilage treatment modalities across the globe is supporting the growth of the market. Based on the treatment modalities, cell-based approaches segment is expected to grow at the fastest rate during the forecast period, due to long term results of this treatment.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cartilage-repair-market/report-sample
The rapid growth in emerging economies and technological advancement in cartilage repair and regeneration products is expected to create opportunities for the manufacturers of cartilage repair products across the globe. However, the high cost of these products and lack of reimbursement for these treatments are the key factors hampering the growth of the global market.
Obesity is a serious health concern in the U.S. The increasing prevalence of obesity is driving the growth of the cartilage repair market in the U.S. According to CDC, during 2011-2012, 35.1% of adult aged 20 years or above were obese. In addition, as published by the Organization for Economic Cooperation and Development (OECD) in the year 2014, the obesity rate in Germany increased from 11.5% in 1999 to 14.7% in 2009. This increase in obesity rate leads to increase in demand for liposuction procedures, which is further accelerating the market growth.
Request For Table of Content at: https://www.psmarketresearch.com/market-analysis/cartilage-repair-market/toc-sample
The key players operating in the global cartilage repair market are Zimmer Biomet Holdings, Inc., Johnson & Johnson, Vericel Corporation, Smith & Nephew PLC, Osiris Therapeutics, Inc., RTI Surgical, Conmed Linvatec, B. Braun Melsungen AG, Anika Therapeutics S. R. L. and Arthrex, Inc.
Bile Duct Cancer Therapeutics Market - Global Industry Size, Growth and Demand, 2023
The global bile duct cancer therapeutics market is expected to witness noticeable growth, in the near future, owing to increasing awareness about cancer and advancements in technologies for cancer treatment. Also, the increasing incidence of cancer is driving the bile duct cancer therapeutics market, globally.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/bile-duct-cancer-therapeutics-market/report-sample
Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma). The most common symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain, abnormal liver function, generalized itching, weight loss, discoloration of stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma) include liver fluke infections, cholangitis and exposure to thorium dioxide. According to American Society of Clinical Oncology (ASCO), less than 3,000 people are affected with the disease, every year, in the U.S. Also, according to Cancer Research UK, about 1,600 people are affected by the disease, every year, in the U.K. The existing treatment options for bile duct cancer (cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and provide only symptomatic relief. The bile duct cancer treatment market has significant unmet need, due to the safety profiles and inadequate efficacy of the existing market products. Therefore, the market offers vast potential for novel participants that can introduce drugs, which could reverse or halt the disease progression and simultaneously, offer good safety profiles and high efficacy.
Pre-Purchase Inquiry at:
https://www.psmarketresearch.com/send-enquiry?enquiry-url=bile-duct-cancer-therapeutics-market
Due to availability of various chemotherapeutic agents for bile duct cancer (cholangiocarcinoma) therapeutics, the market for chemotherapeutic agents is expected to contribute larger revenue to the global bile duct cancer therapeutics market. Innovative bile duct cancer (cholangiocarcinoma) therapeutics are likely to enter into the market, during the forecast period (2017-2023).
Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.
Browse Other Related Report at: https://www.psmarketresearch.com/industry-report/pharmaceuticals
Some of the key players in the global bile duct cancer therapeutics market include, Johnson & Johnson Services, Inc., Dispomedica GmbH, W. L. Gore & Associates, Inc., Boston Scientific Corporation, InSitu Technologies Inc., OptiMed Medizinische Instrumente GmbH, Pauldrach medical Handels- und Vertriebs GmbH, and Medtronic Plc, among several others.
Auto-Injectors Market - Global Industry Insights, Size and Growth, 2023
According to the study, the global auto-injectors market is likely to grow significantly during the forecast period, due to increasing prevalence of anaphylaxis, increasing cases with multiple sclerosis, rising geriatric population and high production of biologics. Additionally, increasing healthcare spending and various beneficial features of auto-injectors also contribute to the growth of the overall market. However, high cost of auto-injectors and stringent regulatory requirements are some of the key factors restraining the growth of global auto-injectors market.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market
As per the findings of the research, the prefilled auto-injectors is the larger product category in the global auto-injectors market, primarily due to increasing availability of user friendly prefilled auto-injectors in disposable form. Based on manufacturing design, standardized auto-injector was the larger contributor to the global auto-injectors market in comparison to customized auto-injector in 2016. Anaphylaxis was the largest application for auto-injectors, followed by multiple sclerosis, rheumatoid arthritis and other diseases, in 2016. According to World Allergy Organization (WAO), the prevalence of anaphylaxis ranged from 2% of the population in the US, to 0.1% of the population in Korea, and 0.6% to 1% of the population in Australia.
Key companies in the auto-injectors market is collaborating to offer advanced auto-injectors. In March 2017, Mylan N.V. entered in a global settlement and license agreement with Genentech Inc and Roche Holding AG in relation to patents for Herceptin (trastuzumab), which provides Mylan N.V. with global licenses for its trastuzumab product. This is expected to help Mylan N.V. to commercialize trastuzumab globally, except in Japan, Brazil and Mexico.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market/report-sample
Some of the key players operating in the global auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.
